GLP1R and chronic kidney disease: HbA1c decreased with lixisenatide as compared to placebo.<h4>Conclusions</h4>In people with CKD and type 2 diabetes the use of short-acting GLP-1 RA lixisenatide did not significantly influence Ao-PWV.